A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials

Annals of Medicine

Volumn 44, Issue 4, 2012, Pages 375-393

  Musso, Giovanni ^a   Gambino, Roberto ^b   Cassader, Maurizio ^b   Pagano, Gianfranco ^b  

^a GRADENIGO HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

BI 10773; Canagliflozin; Dapagliflozin; Diabetes; Diabetes treatment; Hyperglycemia; LX4211; Meta analysis; Renal glucose transporters; Sodium glucose co transport 2 (SGLT2) inhibitors

Indexed keywords

ANTIDIABETIC AGENT; CALCIUM; CANAGLIFLOZIN; CREATININE; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LX 4211; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; POTASSIUM; PROTEIN INHIBITOR; SODIUM; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; URIC ACID;

ACUTE PYELONEPHRITIS; BODY MASS; CALCIUM BLOOD LEVEL; CELL FUNCTION; COCHRANE LIBRARY; CONSTIPATION; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIABETIC DIET; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EMBASE; EVENING DOSAGE; EXERCISE; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFECTION RISK; LIPID BLOOD LEVEL; MEDLINE; META ANALYSIS; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SODIUM BLOOD LEVEL; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; WAIST CIRCUMFERENCE;

BENZHYDRYL COMPOUNDS; BLOOD PRESSURE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM-GLUCOSE TRANSPORT PROTEINS; THIOPHENES;

EID: 84860183617     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2011.560181     Document Type: Review

References (41)

1. American Diabetes Association. Position statement. Diagnosis and classifi cation of diabetes mellitus. Diabetes Care. 2010;33(Suppl1);S62-9.
2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993; 329:977-86.
3. Stratton MI, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321:405-12. (Pubitemid 30609442)
4. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes. 2005;54:1615-25. (Pubitemid 40770750)
5. Gerstein HC. Glucose: a continuous risk factor for cardiovascular disease. Diabet Med. 1997;14(Suppl 3):S25-31. (Pubitemid 27346843)
6. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421-31.
7. American Diabetes Association. Position statement. Standards of medical care in diabetes-2010. Diabetes Care. 2010;33 (Suppl1):S23.
8. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281;2005-12. (Pubitemid 29254858)
9. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-59. (Pubitemid 351831356)
10. Chao EC, Henry RR. SGLT2 inhibition: a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9:551-9.
11. Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75:1272-7.
12. Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin Am Soc Nephrol. 2010;5:133-41.
13. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with noninsulindependent diabetes. Diabetes. 2005;54:3427-34. (Pubitemid 43334332)
14. Polidori D, Sha S, Devineni D, Rothenberg P. The renal glucose threshold is increased in patients with type 2 diabetes: results from a novel method for measuring the renal threshold. ADA 2010 meeting abstract 2186-PO.
15. Ehrenkranz JRL, Lewis NG, Kahn CR, Ross J. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21:31-8.
16. Rossetti L, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987; 79:1510-5. (Pubitemid 17099657)
17. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care. 1990;13:610-30. (Pubitemid 20169143)
18. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.0. The Cochrane Collaboration; updated February 2008. Available at: www.cochrane-handbook.org (accessed 26 May 2009).
19. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. J Clin Epidemiol. 2009;62:1006-12.
20. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodiumglucose cotransport inhibition with dapaglifl ozin in type 2 diabetes. Diabetes Care. 2009;32:650-7.
21. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfi ster M. Dapaglifl ozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85:513-9.
22. Wilding JP, Norwood P, T 'j oen C, Bastien A, List JF, Fiedorek FT. A study of dapaglifl ozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32:1656-62.
23. Wilding JPH, Woo V, Pahor A, Sugg J, Langkilde A, Parikh S. Sustained effectiveness of dapaglifl ozin over 48 weeks in patients with type 2 diabetes poorly controlled with insulin. Diabetologia. 2010;53(S1):S348-9.
24. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapaglifl ozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375: 2223-33.
25. Ferrannini E, Jimenez Ramos S, Salsali A, Tang W, List JF. Dapaglifl ozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Care. 2010;33:2217-24.
26. Strojek K, Hruba V, Elze M, Langkilde A, Parikh S. Effi cacy and safety of dapaglifl ozin in patients with type 2 diabetes mellitus and inadequate glycaemic control on glimepiride monotherapy. Diabetologia. 2010;53(S1):S347-8.
27. Rosenstock J, Polidori D, Zhao Y, Sha S, Arbit D, Usiskin K, et al. Canaglifl ozin, an inhibitor of sodium glucose cotransporter 2, improves glycaemic control, lowers body weight, and improves beta cell function in subjects with type 2 diabetes on background metformin. Diabetologia. 2010; 53(S1):S349.
28. Rothenberg PL, Devineni D, Ghosh A, Polidori AD, Hompesch M, Arnolds S, et al. Canaglifl ozin, a novel inhibitor of sodium glucose co-transporter 2, improved glucose control in subjects with type 2 diabetes: Results of a phase 1b study. Diabetologia. 2010;53(S1):S350-1.
29. Ferrannini E, Seman LI, Seewaldt-Becker E, Hantel S, Pannetti S, Woerle HJ. The potent and highly selective sodium-glucose co-cransporter (SGLT-2) inhibitor BI 10773 is safe and effi cacious as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2010;53(S1):S351.
30. Heise T, Seewaldt-Becker E, Macha S, Hantel S, Huber K, Pinnetti S, et al. BI 10773, a Sodium-glucose co-transporter inhibitor (SGLT-2), is safe and effi cacious following 4-week treatment in patients with type 2 diabetes. Diabetes ADA 2010 meeting abstract 629-P.
31. Seman L, Macha S, Jones P, Marquart A, Port A, Pinnetti S, et al. Safety and tolerability of BI 10773, a sodium-glucose co-transporter (SGLT-2) inhibitor, following 8-days treatment in patients with type 2 diabetes. Diabetes ADA 2010 meeting abstract 571-P.
32. Freiman J, Ruff DA, Frazier KS, Combs K, Turnage A, Shadoan M, et al. LX4211, a dual SGLT2/SGLT1 inhibitor, shows rapid and signifi cant improvement in glycemic control over 28 days in patients with type 2 diabetes (T2DM). Diabetes ADA 2010 meeting abstract 17-LB.
33. Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, et al. Dapaglifl ozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85:520-6.
34. Polidori D, Sha S, Sarich T, Devineni D, Rothenberg PL. Canaglifl ozin lowers the renal threshold for glucose excretion in lean, obese and type 2 diabetic subjects. Diabetologia. 2010;53(Suppl1):S350.
35. Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, et al. Canaglifl ozin, a novel inhibitor of sodium glucose cotransporter 2, induces dose-dependent urinary glucose excretion in healthy subjects. Diabetes ADA 2010 meeting abstract 76-OR.
36. Sarich T, Devineni D, Ghosh A, Wexler D, Shalayda K, Blake J, et al. Canaglifl ozin, a novel inhibitor of sodium glucose co-transporter 2 (SGLT2), increases 24-h urinary glucose excretion and decreases body weight in obese subjects. Diabetes ADA 2010 meeting abstract 567-P.
37. Macdonald FR, Peel JE, Jones HB, Mayers RM, Westgate L, Whaley JM, et al. The novel sodium glucose transporter 2 inhibitor dapaglifl ozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab. 2010;12:1004-12.
38. Ueta K, Torres TP, Mccoy GL, Farmer TD, Condren AB, Whitfi eld T, et al. Normalization of hyperglycemia by inhibiting SGLT2 prevents progressive reduction of hepatic glucokinase (GK) expression and improves hepatic glucose metabolism (HGM) in Zucker diabetic fatty (ZDF) rats. Diabetes ADA 2010 meeting abstract 608-P.
39. Bradford BJ, Allen MS. Phlorizin induces lipolysis and alters meal patterns in both early-and late-lactation dairy cows. J Dairy Sci. 2007;90:1810-5. (Pubitemid 350045405)
40. Devenney J, Harvey S, Rooney S, Godonis H, Washburn W, Whaley J, et al. The effect of dapaglifl ozin, a highly selective SGLT2 inhibitor, on body weight in diet-induced obese rats. Presented at The Obesity Society Annual Scientifi c Meeting 2007; New Orleans, LA, 2007; Abstract 0384.
41. Zhang L, Feng Y, List J, Kasichayanula S, Pfi ster M. Dapaglifl ozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab. 2010;12:510-6.